Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial.
Yamazaki K, Yamanaka T, Shiozawa M, Manaka D, Kotaka M, Gamoh M, Shiomi A, Makiyama A, Munemoto Y, Rikiyama T, Fukunaga M, Ueki T, Shitara K, Shinkai H, Tanida N, Oki E, Sunami E, Ohtsu A, Maehara Y, Yoshino T.
Yamazaki K, et al. Among authors: ohtsu a.
Ann Oncol. 2021 Jan;32(1):77-84. doi: 10.1016/j.annonc.2020.10.480. Epub 2020 Oct 26.
Ann Oncol. 2021.
PMID: 33121997
Free article.
Clinical Trial.